SAN DIEGO--(BUSINESS WIRE)--May 2, 2018--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that Elena Ridloff, CFA, has been appointed
to the newly created position of Senior Vice President, Investor
Relations, leading investor and financial communications activities. She
will report to Steve Davis, ACADIA’s President and Chief Executive
Officer and serve as a member of the company’s Executive Management
This press release features multimedia. View the full release here:
Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)
“We are thrilled to welcome Elena Ridloff to our senior leadership
team,” said Mr. Davis. “Elena’s deep knowledge of the healthcare
industry, strong relationships with the financial community, and keen
understanding of capital markets make her a valuable addition to the
team as we continue to advance our development and commercial efforts
focused on CNS disorders with high unmet needs.”
Ms. Ridloff joins ACADIA from Alexion Pharmaceuticals, where she was
Vice President, Investor Relations reporting to the Chief Financial
Officer and serving as a member of the Operating Committee. In building
and leading the investor relations function at Alexion, she played a key
role in developing and executing the company’s investor relations
strategy and outreach to broaden and strengthen the shareholder base.
Prior to Alexion, she was Chief Executive Officer and Managing Member of
BIOVISIO, an independent consulting firm providing strategic, financial
and investor relations counsel to the life sciences industry. Ms.
Ridloff was also a Managing Director at Maverick Capital, a hedge fund
based in New York, and was responsible for investments in the
biotechnology, pharmaceutical, medical device and life science sectors.
Ms. Ridloff attended the University of Pennsylvania where she earned a
Bachelor of Arts in History and Sociology of Science. She is also a CFA® charterholder.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the advancement of ACADIA’s
development and commercial efforts. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and the fact
that past results of clinical trials may not be indicative of future
trial results. For a discussion of these and other factors, please refer
to ACADIA’s annual report on Form 10-K for the year ended December 31,
2017 as well as ACADIA’s subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All forward-looking
statements are qualified in their entirety by this cautionary statement
and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except
as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180502005581/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.